Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» BioNTech to Receive $120 Million Upfront Payment from Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza
BioNTech to Receive $120 Million Upfront Payment from Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza
BioNTech to Receive $120 Million Upfront Payment from Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza
Submitted by
admin
on August 16, 2018 - 10:26am
Source:
CP Wire
News Tags:
BioNTech
Pfizer
flu vaccines
vaccines
Headline:
BioNTech to Receive $120 Million Upfront Payment from Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza
snippet:
BioNTech will receive $120 million in upfront, equity and near-term research payments
Company is elligible for $305 million in additional payments
BioNTech has additional parnterships with Genentech, Genmab, Eli Lilly, Sanofi and Bayer Animal Health
Do Not Allow Advertisers to Use My Personal information
